Font size:

The FDA is increasing its enforcement actions both for domestic and foreign inspections. Enforcement statistics have not been summarized yet because 2017 has not ended yet. We are certainly seeing more Warning Letters and Import Alerts based on Data Integrity (21 CFR Part 11: Electronic Records; Electronic Signatures. In the past FDA used to issue several Warning Letters to the same firms upon consecutive inspections. Today, after receiving one Warning Letter the next regulatory action is elevated to Import Alert, Consent Decree, and Injunctions for domestic manufacturers. Senior Management must take the initiative in setting the tone of full compliance: Taking "regulatory risks" may no longer be worth the price of getting caught Planned deviations cannot be used as an excuse for not following your written procedures Retesting into compliance has been unacceptable for many years and will no longer be tolerated Senior officials are being held responsible. Today, these "Captains" may go down with the ship - sent to prison and fined millions of dollars FDA's Office of Manufacturing Quality (OMQ) at the Center for Drug Evaluation and Research (CDER) evaluates compliance with current Good Manufacturing Practice (cGMP) for drugs based on inspection reports and evidence gathered by FDA investigators. The office also develops and implements compliance policy and takes advisory actions to protect the public from adulterated drugs in the U.S. market. This year we have seen: Increased use of Contract Manufacturing Organizations (CMO) has increased the regulatory focus on CMO and requirements for Quality Agreements are being enforced There has been an increase in Warning Letters in 2017 An increase in Import Alerts enforcement actions Data Integrity issues are being found more frequently The Seminar: This hands-on seminar provides a comprehensive approach to learning how to proactively prevent non-compliance. There will be intensive reviews on the negative consequences of receiving regulatory enforcement actions. FDA Warning Letters are posted publicly on the CDER web site. Your competitors, shareholders, the public and your patients now become aware of your shortfalls. Many Warning Letters today mandate the hiring of third party consultants, which can be quite expensive. An Injunction will require pharmaceutical companies to spend millions of dollars and require years until you "bounce back." Multimillion disgorgement penalties are being levied along with Injunctions.

Course Audience:
    Your competitors, shareholders, the public and your patients now become aware of your shortfalls. Many Warning Letters today mandate the hiring of third party consultants, which can be quite expensive.

Day 1 Schedule Lecture 1: Introduction and Background Introductions / Participants' Understanding / Participants' Objectives for the Course (Please come prepared to discuss) Background Industry Context Key Concepts Lecture 2: Summary and Highlights of 2017 Enforcement Actions Warning Letters Import Alerts Consent Decrees Injunctions Lecture 3: Penalties and Negative Financial results of Enforcement Actions Detailed Costs and Expenditures for Remediation Loss of Sales and Customers Decreases in Patients Access Loss of Good Reputation Loss of Jobs Lecture 4: ICH Guidelines on Quality Risk Management Science Based Quality Risk Management Quality Risk Management Process Initial Risk Assessment Implement & Verify Appropriate Controls Review Risks & Monitor Controls Day 2 Schedule Lecture 5: Adequate Responses to FDA Comprehensive Corrective and Preventative Action (CAPA) Plans Sincere and Specific timelines Quarterly Follow-ups Adequate but not overwhelming documentation Training Lecture 6: Change in Attitude and Culture Full Support and Commitment of Senior Management Responsibilities to Customers Proactive Not Reactive Lecture 7: Metrics on Improvements Management Involvement Personnel Involvement Positive Increases in Metrics Lead to Positive Attitudes Incentives and Acknowledgements Interactive Session: Group Activities Writing FDA-483 Responses Instructors Evaluation and Recommendations

The course you have selected has limited or no upcoming scheduled training dates!

Please browse similar courses or request more information for assistance.'s training support team will respond within one business day with relevant offerings.

  • Live Pharmaceutical courses

    • All Delivery Types
    • C Classroom (0)
    • V Virtual Live (0)
    • Cv Classroom Virtual (0)
Looking for Live Pharmaceutical courses?

Please call us at 1-866-540-9677.